Clinical Trials Directory

Trials / Completed

CompletedNCT03160677

Blood Pressure Target in Acute Stroke to Reduce hemorrhaGe After Endovascular Therapy

Comparison of Two Strategies for Blood Pressure Control in the Setting of Acute Ischemic Stroke to Reduce Cerebral Hemorrhage After Thrombectomy: Systolic Blood Pressure Target of Less Than 130 mmHg vs Less Than 185 mmHg, for 24 Hours Following Reperfusion, in Patients With Cerebral Infarction Due to Occlusion of the Anterior Circulation

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
320 (actual)
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild · Network
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A randomized, multicenter study comparing two strategies: 1 / standard management of systolic blood pressure according to international recommendations (systolic blood pressure \<185 mm Hg) versus 2 / intensive blood pressure management Systolic with a target \<130 mm Hg.

Detailed description

Patients will be followed for 3 months: * inclusion after reperfusion: clinical evaluation with NIHSS (National Institute of Health Stroke Score) score, measurement of blood pressure. * within 24 hours after reperfusion: blood pressure measurements * at 24 hours: measurement of blood pressure (T0 + 24 h and evaluation of the NIHSS score. * Between 24 and 36 hours :cerebral scan (assessment of hemorrhagic transformations and cerebral infarction volumes). For some centers: Cerebral MRI without injection between H24 and H36 * 72 hours after reperfusion: Cerebral scanner in case of hyperdensity on the initial scanner * 3 months after reperfusion: disability assessment by Rankin score

Conditions

Interventions

TypeNameDescription
OTHERSystolic blood pressure target < 130 mm HgAdaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 130 mm Hg
OTHERSystolic blood pressure target < 185 mm HgAdaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 185 mm Hg

Timeline

Start date
2017-06-21
Primary completion
2019-12-31
Completion
2020-01-31
First posted
2017-05-19
Last updated
2021-08-03

Locations

7 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03160677. Inclusion in this directory is not an endorsement.